MGB Biopharma




MGB Biopharma‘s focus is on developing a completely new class of anti-infective medicine. We have started with antibiotics which are based on Minor Groove Binder (MGBs) compounds.

The Company‘s experienced management team have dedicated their initial focus to the development of a new class of small molecules, with specific antibacterial activity against susceptible and resistant bacteria. In providing a new class of drug to the field of antibacterial resistance, based on a truly novel mechanism of action, MGB Biopharma are relatively unique. A truly new class and novel MoA was last seen in the year 2000.

Contact MGB Biopharma via their website


News archive

06/04/2017   MGB Biopharma Closes $1 million Financing Round...more

03/11/2016   MGB Biopharma Featured In New AMR Report: Page 12 Drug Development By Phase...more
12/09/2016   MGB Biopharma Granted FDA Qualified Infectious Disease Product (QIPD) Designation...more
19/05/2016   MGB Biopharma Welcomes Recommendations for the World to Defeat Suerbugs...more
09/05/2016   MGB Biopharma has pre-IND meeting with FDA for MGB-BP-3 strategy in the US...more
16/02/2016   MGB Biopharma and the University of Strathclyde (UoS) announce new agreement...more

09/12/2015   MGB Biopharma successfully completes Phase I clinical trial...more
17/11/2015   MGB Biopharma Completes Feasibility Study with Topical Antibacterial MGB-BP-3...more
10/09/2015   MGB Biopharma Wins Scottish Business Award...more
21/07/2015   MGB Biopharma commences Phase I clinical trial...more
02/06/2015   MGB Biopharma announces new Formulation for treatment of hospital-acquired Infections...more
15/05/2015   MGB Biopharma Endorses Review on Antimicrobial Resistance...more
12/01/2015   MGB Biopharma issues update on 2014 business performance...more

08/12/2014   MGB Biopharma Announces Collaborations with Almac Group and Encap Drug Delivery...more
01/12/2014   MGB Biopharma Shortlisted for Scottish Enterprise Life Sciences Award...more
26/11/2014   MGB Biopharma in the News–European Pharmaceutical Contractor...more
17/09/2014   MGB Biopharma Secures £4.0m to Advance its Novel Lead Antibacterial...more
26/08/2014   MGB Biopharma In the News – MedNous...more
09/06/2014   MGB Biopharma Receives £1.3m BioMedical Catalyst Grant...more

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

BioPartner UK is a member of

Sponsors Alliance

Prompt Payment Code